In the present study, we found that subjects with higher circulating PCSK9 had progressively worse cardiometabolic risk profiles in women, including incident high LDL-cholesterol, elevated triglycerides, hypertension, type 2 diabetes, and metabolic syndrome. This evidence concerns the gene PCSK9 and metabolic syndrome.